New investor Lilly Asia Ventures helped the cancer testing kit provider increase its overall funding to more than $160m.
China-based cancer diagnostics technology provider New Horizon Health completed a $30m series E round on Monday backed by pharmaceutical firm Eli Lilly through its Lilly Asia Ventures unit.
Investment firm Rock Springs Capital led the round, which included CR-CP Life Science Fund, a joint venture for conglomerates China Resources Group and Charoen Pokphand, as well as OrbiMed, Cormorant Asset Management, Qiming Venture Partners and Octagon Capital.
New Horizon has developed testing kits to diagnose stomach and colon cancer in the…
